Etravirine vs Rilpivirine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Etravirine · Intelence

Marketed by Johnson & Johnson

Approved in HIVsmall molecule
Reliable signal

NCT00254046 · Phase 3 · completed

Participants were randomized and blinded to etravirine or placebo on top of background therapy. A significantly larger share of patients on etravirine achieved viral suppression than on placebo.

Reported efficacy

Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen. (24 weeks): Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005 (met)

Result source: NCT00254046

Rilpivirine · Edurant

Marketed by Johnson & Johnson

Approved in HIVsmall molecule
Reliable signal

NCT00540449 · Phase 3 · completed

This was a large (690-participant), randomized, quadruple-blinded, active-controlled (efavirenz) phase 3 trial with a hard clinical endpoint (confirmed viral load <50 copies/mL). The pre-specified non-inferiority margin was clearly met, with the confidence interval for the treatment difference falling entirely within the allowed -12% boundary, so rilpivirine was shown to be as effective as efavirenz on the primary measure despite a somewhat higher rate of virologic failure and resistance emergence as a secondary finding.

Next expected readout: December 2028 · NCT07637877 (registry estimate)

Reported efficacy

Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%. (met)

Result source: NCT00540449

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEtravirineRilpivirine
HIV-1 RNA below 50 copies/mL (week 48)56% vs 39%a+17 vs placebowk 24NCT0025404694% vs 94%vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
12 other results
  • 93.7% vs 89.9% wk 24 · n 317 · Phase 3 · primary NCT01252940
  • 95% vs 96% wk 48 · n 252 · Phase 3 · primary NCT02429791
  • 93.7% vs 93.9% wk 48 · n 316 · Phase 3 · primary NCT02345252
  • 90% vs 92% wk 48 · n 438 · Phase 3 · primary NCT02345226
  • 85.8% vs 81.6% wk 48 · n 394 · Phase 3 · primary NCT01309243
  • 97% vs 98% DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 98% vs 96% wk 24 · n 252 · Phase 3 · secondary NCT02429791
  • 93.9% vs 96.2% wk 48 · n 213 · Phase 3 · secondary NCT01709084
  • 89.3% vs 92.1% wk 48 · n 317 · Phase 3 · secondary NCT01252940
  • 89.2% vs 88.5% wk 96 · n 316 · Phase 3 · secondary NCT02345252
  • 85.2% vs 85.1% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 77.9% vs 72.4% wk 96 · n 394 · Phase 3 · secondary NCT01309243
HIV-1 RNA 50 copies/mL or more (week 48)—Not posted · NCT002550990.6% vs 1%vs FTC/RPV/TDFwk 96 · n 316NCT02345252
3 other results
  • 0.7% vs 0.9% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 0.6% vs 0% wk 48 · n 316 · Phase 3 · secondary NCT02345252
  • 1.1% vs 0.9% wk 48 · n 438 · Phase 3 · secondary NCT02345226
CD4 count, change (week 48)—Not posted · NCT0025509928 vs 18.4vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
14 other results
  • 42 vs 42.4 DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 12 vs 16 wk 96 · n 283 · Phase 3 · secondary NCT02345252
  • 12 vs 6 wk 96 · n 370 · Phase 3 · secondary NCT02345226
  • 278 vs 259 wk 96 · n 327 · Phase 3 · secondary NCT01309243
  • 32.3 vs 41.8 wk 48 · n 252 · Phase 3 · secondary NCT02429791
  • 9 vs -1 wk 48 · n 296 · Phase 3 · secondary NCT02345252
  • 23 vs 12 wk 48 · n 390 · Phase 3 · secondary NCT02345226
  • 10 vs -7 wk 48 · n 287 · Phase 3 · secondary NCT01252940
  • 200 vs 191 wk 48 · n 357 · Phase 3 · secondary NCT01309243
  • 16.2 vs 47.4 wk 24 · n 252 · Phase 3 · secondary NCT02429791
  • 20 vs 32 wk 24 · n 298 · Phase 3 · secondary NCT01252940
  • 145.9 vs 159.8 25 mg · wk 96 · n 93 · Phase 2 · secondary NCT00110305
  • 158.9 vs 159.8 150 mg · wk 96 · n 91 · Phase 2 · secondary NCT00110305
  • 172 vs 159.8 75 mg · wk 96 · n 95 · Phase 2 · secondary NCT00110305

HIV-1 RNA below 50 copies/mL (week 48)

Etravirine
56% vs 39%a+17 vs placebowk 24NCT00254046
Rilpivirine
94% vs 94%vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
12 other results
  • 93.7% vs 89.9% wk 24 · n 317 · Phase 3 · primary NCT01252940
  • 95% vs 96% wk 48 · n 252 · Phase 3 · primary NCT02429791
  • 93.7% vs 93.9% wk 48 · n 316 · Phase 3 · primary NCT02345252
  • 90% vs 92% wk 48 · n 438 · Phase 3 · primary NCT02345226
  • 85.8% vs 81.6% wk 48 · n 394 · Phase 3 · primary NCT01309243
  • 97% vs 98% DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 98% vs 96% wk 24 · n 252 · Phase 3 · secondary NCT02429791
  • 93.9% vs 96.2% wk 48 · n 213 · Phase 3 · secondary NCT01709084
  • 89.3% vs 92.1% wk 48 · n 317 · Phase 3 · secondary NCT01252940
  • 89.2% vs 88.5% wk 96 · n 316 · Phase 3 · secondary NCT02345252
  • 85.2% vs 85.1% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 77.9% vs 72.4% wk 96 · n 394 · Phase 3 · secondary NCT01309243

HIV-1 RNA 50 copies/mL or more (week 48)

Etravirine
—Not posted · NCT00255099
Rilpivirine
0.6% vs 1%vs FTC/RPV/TDFwk 96 · n 316NCT02345252
3 other results
  • 0.7% vs 0.9% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 0.6% vs 0% wk 48 · n 316 · Phase 3 · secondary NCT02345252
  • 1.1% vs 0.9% wk 48 · n 438 · Phase 3 · secondary NCT02345226

CD4 count, change (week 48)

Etravirine
—Not posted · NCT00255099
Rilpivirine
28 vs 18.4vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
14 other results
  • 42 vs 42.4 DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 12 vs 16 wk 96 · n 283 · Phase 3 · secondary NCT02345252
  • 12 vs 6 wk 96 · n 370 · Phase 3 · secondary NCT02345226
  • 278 vs 259 wk 96 · n 327 · Phase 3 · secondary NCT01309243
  • 32.3 vs 41.8 wk 48 · n 252 · Phase 3 · secondary NCT02429791
  • 9 vs -1 wk 48 · n 296 · Phase 3 · secondary NCT02345252
  • 23 vs 12 wk 48 · n 390 · Phase 3 · secondary NCT02345226
  • 10 vs -7 wk 48 · n 287 · Phase 3 · secondary NCT01252940
  • 200 vs 191 wk 48 · n 357 · Phase 3 · secondary NCT01309243
  • 16.2 vs 47.4 wk 24 · n 252 · Phase 3 · secondary NCT02429791
  • 20 vs 32 wk 24 · n 298 · Phase 3 · secondary NCT01252940
  • 145.9 vs 159.8 25 mg · wk 96 · n 93 · Phase 2 · secondary NCT00110305
  • 158.9 vs 159.8 150 mg · wk 96 · n 91 · Phase 2 · secondary NCT00110305
  • 172 vs 159.8 75 mg · wk 96 · n 95 · Phase 2 · secondary NCT00110305
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Etravirine: 7 of 7 rows · Rilpivirine: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEtravirine
Rows use multiple source trials
Rilpivirine
Rows use multiple source trials
CD4+
absolute change · cells/uL
No placebo or comparator arm
149.5 cells/uL @ 192wka,b,c
NCT00128830 · Phase 2 · registry result, not featured evidence
148.76 cells/uL @ 192wkd,a,b,c
NCT01266902 · Phase 3 · registry result, not featured evidence
show 3 more doses
133.56 cells/uL @ 192wk
NCT01266902 · Phase 3 · registry result, not featured evidence
132.73 cells/uL @ 192wk
NCT01266902 · Phase 3 · registry result, not featured evidence
91.69 cells/uL @ 192wk
NCT01266902 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies
responder rate · % of participants
No placebo or comparator arm
45.5% (n=22) @ 48wk400/100 mgd,a,b,e
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
50% (n=22) @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
85% (n=252) @ 148wka,b,e
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
84% (n=261) @ 148wkDTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
Virologic Response Rate Lt50 Copies
responder rate · % of participants
Maintenance
62% vs 44% placebo @ 24wkf,b,c,g
NCT00255099 · Phase 3 · sponsor-reported, not registry data
76% (n=346) vs 78.8% (n=344) Efavirenz @ 96wk*f,b,c,g
Responder
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 263 Participants as posted
Dropout rate
n/a: no completion milestoneh
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
20.3%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
36%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
40%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
24.8%
NCT00665847 · Phase 2 · registry result, not featured evidence
20.3%
NCT00903682 · Phase 2 · registry result, not featured evidence
34.1%
NCT00128830 · Phase 2 · registry result, not featured evidence
5%Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
16.7%Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
—200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
17.9%
NCT00871234 · Phase 1 · registry result, not featured evidence
0%
NCT01625169 · Phase na · registry result, not featured evidence · combination
—
NCT01427504 · Phase na · registry result, not featured evidence · combination
24.3%i
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 32 more results
20%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
5.2%DTG + RPV
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Continuation Phase)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early + Late Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
6.1%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
7.5%
NCT01709084 · Phase 3 · registry result, not featured evidence
22.3%RPV (TMC278-TiDP6-C209 [C209] and
NCT01266902 · Phase 3 · registry result, not featured evidence
25.2%Rilpivirine (RPV) (TMC278-C204 [C2
NCT01266902 · Phase 3 · registry result, not featured evidence
12.7%FTC/RPV/TAF
NCT02345252 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
15.7%FTC/RPV/TAF
NCT02345226 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From EFV/FT
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345226 · Phase 3 · registry result, not featured evidence
8.1%
NCT01252940 · Phase 3 · registry result, not featured evidence
21%
NCT01309243 · Phase 3 · registry result, not featured evidence
0%
NCT04012931 · Phase 2 · registry result, not featured evidence
30.6%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
40%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
33.3%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%12.5 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
12.1%
NCT02165202 · Phase 2 · registry result, not featured evidence
4%
NCT01286740 · Phase 2 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
7.1%
NCT01562886 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
6.7%h
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
3.8%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
4%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
8%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
7.9%
NCT00665847 · Phase 2 · registry result, not featured evidence
7.6%
NCT00903682 · Phase 2 · registry result, not featured evidence
4.7%
NCT00128830 · Phase 2 · registry result, not featured evidence
—Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
—200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
7.1%
NCT00871234 · Phase 1 · registry result, not featured evidence
—
NCT01625169 · Phase na · registry result, not featured evidence · combination
—
NCT01427504 · Phase na · registry result, not featured evidence · combination
3.5%i
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 32 more results
5.3%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
2.4%DTG + RPV
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Continuation Phase)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early + Late Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
4.2%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT01709084 · Phase 3 · registry result, not featured evidence
3%RPV (TMC278-TiDP6-C209 [C209] and
NCT01266902 · Phase 3 · registry result, not featured evidence
2.5%Rilpivirine (RPV) (TMC278-C204 [C2
NCT01266902 · Phase 3 · registry result, not featured evidence
0.6%FTC/RPV/TAF
NCT02345252 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
1.1%FTC/RPV/TAF
NCT02345226 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From EFV/FT
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345226 · Phase 3 · registry result, not featured evidence
0.9%
NCT01252940 · Phase 3 · registry result, not featured evidence
3%
NCT01309243 · Phase 3 · registry result, not featured evidence
—
NCT04012931 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—15 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—12.5 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—
NCT02165202 · Phase 2 · registry result, not featured evidence
—
NCT01286740 · Phase 2 · registry result, not featured evidence
—50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
—
NCT01562886 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
10%h
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
15.2%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
8%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
16%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
5%
NCT00665847 · Phase 2 · registry result, not featured evidence
13.9%
NCT00903682 · Phase 2 · registry result, not featured evidence
21.8%
NCT00128830 · Phase 2 · registry result, not featured evidence
25%Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
50%Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
0%200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
0%200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
0%
NCT00871234 · Phase 1 · registry result, not featured evidence
0%
NCT01625169 · Phase na · registry result, not featured evidence · combination
20%
NCT01427504 · Phase na · registry result, not featured evidence · combination
11.6%i
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 32 more results
9.4%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
—DTG + RPV
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
3.2%DTG + RPV (Continuation Phase)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
13.5%DTG + RPV (Early + Late Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
4%DTG + RPV (Early Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
5.8%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
14.6%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
7.3%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
7.5%
NCT01709084 · Phase 3 · registry result, not featured evidence
4.4%RPV (TMC278-TiDP6-C209 [C209] and
NCT01266902 · Phase 3 · registry result, not featured evidence
7.6%Rilpivirine (RPV) (TMC278-C204 [C2
NCT01266902 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF
NCT02345252 · Phase 3 · registry result, not featured evidence
11.4%FTC/RPV/TAF (Double-Blind Phase)
NCT02345252 · Phase 3 · registry result, not featured evidence
5.3%Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
0%Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF
NCT02345226 · Phase 3 · registry result, not featured evidence
12.3%FTC/RPV/TAF (Double-Blind Phase)
NCT02345226 · Phase 3 · registry result, not featured evidence
4.8%Open-Label FTC/RPV/TAF From EFV/FT
NCT02345226 · Phase 3 · registry result, not featured evidence
0%Open-Label FTC/RPV/TAF From FTC/RP
NCT02345226 · Phase 3 · registry result, not featured evidence
6.6%
NCT01252940 · Phase 3 · registry result, not featured evidence
9.1%
NCT01309243 · Phase 3 · registry result, not featured evidence
0%
NCT04012931 · Phase 2 · registry result, not featured evidence
16.7%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%12.5 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
4.4%
NCT02165202 · Phase 2 · registry result, not featured evidence
2%
NCT01286740 · Phase 2 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
0%
NCT01562886 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
h
cough 2.8%
upper respiratory tract infection 2.8%
pregnancy 2.2%
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
400 mg once daily
elevated level of transaminase 11.4%
hyperbilirubinemia 7.6%
hyperlipidemia 7.6%
NCT00959894 · Phase 2 · registry result, not featured evidence
400/100 mg
cough 16%
headache 12%
influenza 12%
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
300/100 mg
cough 20%
nausea 16%
blood bilirubin increased 12%
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
upper respiratory tract infection 26.7%
diarrhoea 15.8%
cough 12.9%
NCT00665847 · Phase 2 · registry result, not featured evidence
nasopharyngitis 21.5%
headache 16.5%
diarrhoea 10.1%
NCT00903682 · Phase 2 · registry result, not featured evidence
diarrhoea 17.5%
upper respiratory tract infection 17.1%
sinusitis 11.4%
NCT00128830 · Phase 2 · registry result, not featured evidence
blood bicarbonate decreased 90%
blood sodium decreased 70%
nasal congestion 70%
NCT01504841 · Phase 1/2 · registry result, not featured evidence
cough 100%
nasal congestion 100%
rhinorrhoea 100%
NCT01504841 · Phase 1/2 · registry result, not featured evidence
200 mg + 200 mg
headache 18.8%
toothache 12.5%
diarrhoea 6.3%
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
200 mg + 600/100 mg + 200 mg
rash maculo-papular 20%
scleral hyperaemia 20%
headache 13.3%
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
headache 14.3%
constipation 10.7%
diarrhea 7.1%
NCT00871234 · Phase 1 · registry result, not featured evidence
breast tenderness 66.7%
diarrhea 11.1%
headache 11.1%
NCT01625169 · Phase na · registry result, not featured evidence · combination
altered taste 64%
headache 16%
rash 16%
NCT01427504 · Phase na · registry result, not featured evidence · combination
i
upper respiratory tract infection 15.3%
diarrhoea 14.7%
headache 14.5%
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 28 more results
headache 17.9%
nausea 16.8%
nasopharyngitis 14.7%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
arthralgia 0%
back pain 0%
bronchitis 0%
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 20.6%
headache 14.7%
diarrhoea 13.9%
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 10.7%
headache 9.5%
diarrhoea 8.7%
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
DTG 50 mg + RPV 25 mg
arthralgia 0%
asthenia 0%
back pain 0%
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
DTG 50 mg + RPV 25 mg
nasopharyngitis 18.4%
upper respiratory tract infection 14.2%
bronchitis 10.7%
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
DTG 50 mg + RPV 25 mg
nasopharyngitis 8%
upper respiratory tract infection 7.3%
arthralgia 6.5%
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 29.6%
headache 17.8%
urinary tract infection 13.6%
NCT01709084 · Phase 3 · registry result, not featured evidence
pregnancy 1.9%
headache 1.1%
alanine aminotransferase increased 0.8%
NCT01266902 · Phase 3 · registry result, not featured evidence
facial wasting 1.7%
hepatitis c 1.7%
hypertension 1.7%
NCT01266902 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.5%
upper respiratory tract infection 14.9%
diarrhoea 10.8%
NCT02345252 · Phase 3 · registry result, not featured evidence
back pain 10.5%
conjunctivitis allergic 10.5%
cough 10.5%
NCT02345252 · Phase 3 · registry result, not featured evidence
cough 17.6%
nasopharyngitis 17.6%
pyrexia 17.6%
NCT02345252 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 16.9%
nasopharyngitis 11.6%
cough 10.3%
NCT02345226 · Phase 3 · registry result, not featured evidence
cough 9.5%
diarrhoea 9.5%
eczema 9.5%
NCT02345226 · Phase 3 · registry result, not featured evidence
rhinitis 16%
nasopharyngitis 12%
bronchitis 8%
NCT02345226 · Phase 3 · registry result, not featured evidence
nasopharyngitis 11%
diarrhoea 10.7%
headache 9.8%
NCT01252940 · Phase 3 · registry result, not featured evidence
diarrhoea 17.5%
nausea 16.5%
upper respiratory tract infection 14.5%
NCT01309243 · Phase 3 · registry result, not featured evidence
vomiting 15.4%
alanine aminotransferase increased 11.5%
abdominal pain 7.7%
NCT04012931 · Phase 2 · registry result, not featured evidence
25 mg
upper respiratory tract infection 55.6%
influenza 41.7%
cough 27.8%
NCT00799864 · Phase 2 · registry result, not featured evidence
25 mg
upper respiratory tract infection 60%
toothache 40%
alanine aminotransferase increased 20%
NCT00799864 · Phase 2 · registry result, not featured evidence
25 mg
upper respiratory tract infection 55.6%
decreased appetite 22.2%
diarrhoea 22.2%
NCT00799864 · Phase 2 · registry result, not featured evidence
15 mg
upper respiratory tract infection 100%
anaemia 50%
dermatitis atopic 50%
NCT00799864 · Phase 2 · registry result, not featured evidence
12.5 mg
upper respiratory tract infection 100%
cough 50%
lower respiratory tract infection 50%
NCT00799864 · Phase 2 · registry result, not featured evidence
injection site pain 75% (placebo 40.5%)
injection site pruritus 36.3% (placebo 11.9%)
injection site swelling 36.3% (placebo 7.1%)
NCT02165202 · Phase 2 · registry result, not featured evidence
diarrhoea 16.3%
upper respiratory tract infection 14.3%
insomnia 12.2%
NCT01286740 · Phase 2 · registry result, not featured evidence
50mg/25mg
headache 6.3%
vessel puncture site bruise 6.3%
vomiting 6.3%
NCT03984838 · Phase 1 · registry result, not featured evidence
insomnia 23.1%
NCT01562886 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eAssessment timepoints differ: 148 weeks versus 48 weeks.
  6. fThe reported result categories differ.
  7. gAssessment timepoints differ: 96 weeks versus 24 weeks.
  8. hPopulation comparability has not been reviewed for these studies.
  9. iPopulation comparability has not been reviewed for 31 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Etravirine

HIV-1 RNA Less Than 50 Copies 0.87% (n=79) @ 24wk400 mg once daily
event count · % of participants
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 2 more results
0.77% (n=79) @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
0.71% (n=79) @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
HIV-1 RNA LT 200 Copies 0.89% (n=79) @ 24wk400 mg once daily
event count · % of participants
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 2 more results
0.82% (n=79) @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
0.77% (n=79) @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
CD4 46 count @ 4wk400/100 mg
absolute change · count
No placebo or comparator arm
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
72 count @ 12wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
83 count @ 24wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
132 count @ 48wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
55 count @ 4wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
31 count @ 12wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
54 count @ 24wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
105 count @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Virological Response 50 Copies Snapshot 45.5% (n=22) @ 48wk400/100 mg
responder rate · % of participants
No placebo or comparator arm
Virologic Response
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
50% (n=22) @ 48wk300/100 mg
Virologic Response
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA -1.8 copies/mL @ 4wk400/100 mg
absolute change · copies/mL
No placebo or comparator arm
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
-2 copies/mL @ 12wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.8 copies/mL @ 24wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.4 copies/mL @ 48wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.9 copies/mL @ 4wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.7 copies/mL @ 12wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.8 copies/mL @ 24wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.4 copies/mL @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Time to Viral Suppression 2.5 months400/100 mg
time to event · months
No placebo or comparator arm
Plasma VL < 50 copies/mL
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 76 days as posted
show 1 more result
2.33 months*300/100 mg
Plasma VL < 50 copies/mL
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 71 days as posted
Time to Virologic Failure NA months400/100 mg
time to event · months
No placebo or comparator arm
Virologic Responders (Plasma VL < 50 copies/mL)
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
10.45 months*300/100 mg
Virologic Responders (Plasma VL < 50 copies/mL)
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 318 days as posted
Virologic 52.5% (n=101) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT00665847 · Phase 2 · registry result, not featured evidence
HIV-1 RNA -1.53 log @ 48wk
absolute change · log
No placebo or comparator arm
NCT00665847 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 400 Copies Per 75.9% (n=79) vs 74.4% (n=78) Efavirenz @ 48wk
event count · % of participants
NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 60 Number of participants as posted
show 1 more result
81% (n=79) vs 79.5% (n=78) Efavirenz @ 48wk*
NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 64 Number of participants as posted
CD4 69.96 vs 72.45 Efavirenz count @ 2wk
absolute change · count
NCT00903682 · Phase 2 · registry result, not featured evidence
show 5 more results
128.14 vs 121.62 Efavirenz count @ 6wk
NCT00903682 · Phase 2 · registry result, not featured evidence
143.24 vs 151.46 Efavirenz count @ 12wk
NCT00903682 · Phase 2 · registry result, not featured evidence
182.01 vs 174.08 Efavirenz count @ 24wk
NCT00903682 · Phase 2 · registry result, not featured evidence
213.45 vs 180.18 Efavirenz count @ 36wk
NCT00903682 · Phase 2 · registry result, not featured evidence
205.11 vs 221.39 Efavirenz count @ 48wk
NCT00903682 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 58% (n=181) @ 96wk
responder rate · % of participants
No placebo or comparator arm
Viral load (VL) less than 50 copies/mL
NCT00128830 · Phase 2 · registry result, not featured evidence · converted to % from 105 Participants as posted
show 1 more result
70.4% (n=98) @ 192wk*
Viral load (VL) less than 50 copies/mL
NCT00128830 · Phase 2 · registry result, not featured evidence · converted to % from 69 Participants as posted

+ 5 further endpoints in the CSV export.

Rilpivirine

Virologic Response Rate Lt50 Copies 82.4% (n=346) vs 81.7% (n=344) Efavirenz @ 48wk
responder rate · % of participants
Virologic Response HIV RNA <50 copies/mL at Wk 48
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 285 Participants as posted
Virologic Response Rate Lt50 Copies 76.6% (n=346) vs 77.9% (n=344) Efavirenz @ 96wk
responder rate · % of participants
Virologic Response, <50 copies/ml
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 265 Participants as posted
Virologic Response Rate Lt400 Copies 85.8% (n=346) vs 85.2% (n=344) Efavirenz @ 48wk
responder rate · % of participants
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 297 Participants as posted
show 1 more result
78.9% (n=346) vs 80.8% (n=344) Efavirenz @ 96wk*
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 273 Participants as posted
CD4+ 195.5 vs 181.6 Efavirenz cells/uL @ 48wk
absolute change · cells/uL
Absolute cell count, Week 48
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 1 more result
188.6 vs 170.7 Efavirenz cells/uL @ 48wk
Absolute cell count, Week 48
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
CD4+ 220.7 vs 226.7 Efavirenz cells/uL @ 96wk
absolute change · cells/uL
Absolute cell count, Week 96
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 1 more result
234.5 vs 212 Efavirenz cells/uL @ 96wk
Absolute cell count, Week 96
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
Virological Response 50 Copies TLOVR 85.6% (n=340) vs 81.7% (n=338) Efavirenz @ 48wk
event count · % of participants
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 291 Participants as posted
show 1 more result
79.1% (n=340) vs 76.3% (n=338) Efavirenz @ 96wk*
Responder
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 269 Participants as posted
Virological Response 50 Copies Snapshot 82.6% (n=340) vs 78.4% (n=338) Efavirenz @ 48wk
event count · % of participants
Virologic Response (<50 copies/mL)
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 281 Participants as posted
show 1 more result
76.2% (n=340) vs 75.1% (n=338) Efavirenz @ 96wk*
Virologic response (<50 copies/mL)
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 259 Participants as posted
Virological Response 400 Copies TLOVR 88.2% (n=340) vs 84.6% (n=338) Efavirenz @ 48wk
event count · % of participants
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 300 Participants as posted
show 1 more result
83.2% (n=340) vs 79.9% (n=338) Efavirenz @ 96wk*
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 283 Participants as posted
CD4+ 145.9 vs 159.8 Efavirenz cells/uL @ 96wk25 mg
absolute change · cells/uL
NCT00110305 · Phase 2 · registry result, not featured evidence
show 14 more results
158.9 vs 159.8 Efavirenz cells/uL @ 96wk150 mg
NCT00110305 · Phase 2 · registry result, not featured evidence
172 vs 159.8 Efavirenz cells/uL @ 96wk75 mg
NCT00110305 · Phase 2 · registry result, not featured evidence
42 vs 42.4 CAR cells/uL @ 24wkDTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
28 vs 18.4 CAR cells/uL @ 48wkDTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
16.2 vs 47.4 Current Antiretroviral Regimen (CAR) cells/uL @ 24wk
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
32.3 vs 41.8 Current Antiretroviral Regimen (CAR) cells/uL @ 48wk
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
9 vs -1 FTC/RPV/TDF cells/uL @ 48wk
NCT02345252 · Phase 3 · registry result, not featured evidence
12 vs 16 FTC/RPV/TDF cells/uL @ 96wk
NCT02345252 · Phase 3 · registry result, not featured evidence
23 vs 12 EFV/FTC/TDF cells/uL @ 48wk
NCT02345226 · Phase 3 · registry result, not featured evidence
12 vs 6 EFV/FTC/TDF cells/uL @ 96wk
NCT02345226 · Phase 3 · registry result, not featured evidence
20 vs 32 SBR cells/uL @ 24wk
NCT01252940 · Phase 3 · registry result, not featured evidence
10 vs -7 SBR cells/uL @ 48wk
NCT01252940 · Phase 3 · registry result, not featured evidence
200 vs 191 EFV/FTC/TDF cells/uL @ 48wk
NCT01309243 · Phase 3 · registry result, not featured evidence
278 vs 259 EFV/FTC/TDF cells/uL @ 96wk
NCT01309243 · Phase 3 · registry result, not featured evidence
HIVTSQc 0 vs 0 Current Antiretroviral Regimen (CAR) score @ 4wk
absolute change · score
Total score, Week 4
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
HIVTSQc 1 vs 0 Current Antiretroviral Regimen (CAR) score @ 24wk
absolute change · score
Total score, Week 24
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
HIVTSQc 0.5 vs 0 Current Antiretroviral Regimen (CAR) score @ 48wk
absolute change · score
Total score, Week 48
NCT02429791 · Phase 3 · registry result, not featured evidence · combination

+ 18 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Etravirine's landscape · Rilpivirine's landscape